July 13, 2017
ODAC backs U.S. approval of Mylan’s and Biocon’s cancer drug
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Mylan’s and Biocon’s proposed biosimilar trastuzumab.
